CEL-SCI Corp. Company Profile

Description: CEL-SCI Corp.

CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company is also developing CEL-1000, which is derived from a pre-clinical technology called ‘Ligand Epitope Antigen Presentation System’ to stimulate the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer; and CEL-2000 for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.

Company Profile



 CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemaggl...

Close Viewer



 CEL-SCI Corporation (CEL-SCI) is a biotechnology company. It focuses on the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The company’s product portfolio comprises of Multikine (Leukocyte I...

Close Viewer

Cart Summary

Cart items will instantly download upon purchase.

There are no items in your cart
Your Savings: $0.00
Your Total: $0.00

Contact Info

8229 Boone Boulevard, Suite 802, Vienna,VA 22182, United States

Executive Team

Mr. Maximilian De Clara
80, Founder, Chairman and Pres
Mr. Geert R. Kersten Esq.
52, Chief Exec. Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
Ms. Patricia B. Prichep
59, Sr. VP of Operations and Sec.
Dr. Daniel H. Zimmerman Ph.D.
69, Sr. VP of Research and Cellular Immunology
Mr. John Cipriano
68, Sr. VP of Regulatory Affairs


Celldex Therapeutics, Inc.